Research Article

AHCYL1 Is a Novel Biomarker for Predicting Prognosis and Immunotherapy Response in Colorectal Cancer

Figure 2

Relationship among AHCYL1, tumor mutation burden (TMB), and immunotherapy response to CRC patients. (a) The scores of 16 immune cells. (b) The TMB in tissues with different AHCYL1 expressions. (c) The value of the tumor immune dysfunction and exclusion (TIDE). (d) The response to immunotherapy (; ns: not significant).
(a)
(b)
(c)
(d)